Article
Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Neurobiology of disease - 1 May 2012
Jia Haiqun, Pallos Judit, Jacques Vincent, Lau Alice, Tang Bin, Cooper Andrew, Syed Adeela, Purcell Judith, Chen Yi, Sharma Shefali, Sangrey Gavin R, Darnell Shayna B, Plasterer Heather, Sadri-Vakili Ghazaleh, Gottesfeld Joel M, Thompson Leslie M, Rusche James R, Marsh J Lawrence, Thomas Elizabeth A
Abstract excerpt
We have previously demonstrated amelioration of Huntington's disease (HD)-related phenotypes in R6/2 transgenic mice in response to treatment with the novel histone deacetylase (HDAC) inhibitor 4b. Here we have measured the selectivity profiles of 4b and related compounds against class I and class II HDACs and have tested their ability to restore altered expression of genes related to HD pathology in mice and to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.